Neil Davie

2.6k total citations
41 papers, 2.0k citations indexed

About

Neil Davie is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Neil Davie has authored 41 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 19 papers in Cardiology and Cardiovascular Medicine and 6 papers in Surgery. Recurrent topics in Neil Davie's work include Pulmonary Hypertension Research and Treatments (37 papers), Cardiovascular Function and Risk Factors (7 papers) and Cardiovascular Issues in Pregnancy (7 papers). Neil Davie is often cited by papers focused on Pulmonary Hypertension Research and Treatments (37 papers), Cardiovascular Function and Risk Factors (7 papers) and Cardiovascular Issues in Pregnancy (7 papers). Neil Davie collaborates with scholars based in United Kingdom, United States and Germany. Neil Davie's co-authors include Kurt R. Stenmark, Maria G. Frid, John Τ. Reeves, John Wharton, Nicholas W. Morrell, Paul D. Upton, Todd C. Carpenter, Julia M. Polak, Evgenia Gerasimovskaya and Hossein Ardeschir Ghofrani and has published in prestigious journals such as Circulation, American Journal of Respiratory and Critical Care Medicine and Journal of Applied Physiology.

In The Last Decade

Neil Davie

41 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Neil Davie United Kingdom	18	1.6k	880	415	335	270	41	2.0k
Mark L. Ormiston Canada	23	1.3k 0.8×	484 0.6×	940 2.3×	164 0.5×	298 1.1×	39	2.3k
Trina K. Jeffery Australia	13	998 0.6×	420 0.5×	357 0.9×	304 0.9×	156 0.6×	19	1.4k
Julie W. Harral United States	18	864 0.5×	333 0.4×	513 1.2×	186 0.6×	186 0.7×	37	1.4k
Mélanie Eyries France	23	1.1k 0.7×	557 0.6×	438 1.1×	64 0.2×	343 1.3×	54	1.9k
Benoît Ranchoux France	14	971 0.6×	423 0.5×	535 1.3×	98 0.3×	169 0.6×	17	1.4k
Bahil Ghanim Austria	27	1.0k 0.6×	234 0.3×	379 0.9×	158 0.5×	336 1.2×	60	1.7k
Nana Burns United States	16	769 0.5×	315 0.4×	375 0.9×	213 0.6×	136 0.5×	26	1.2k
Amal Houssaïni France	18	811 0.5×	279 0.3×	602 1.5×	191 0.6×	178 0.7×	28	1.4k
Kyra L. Jordan United States	25	502 0.3×	288 0.3×	759 1.8×	295 0.9×	452 1.7×	68	1.8k
Nicolas Ricard France	15	698 0.4×	226 0.3×	669 1.6×	94 0.3×	242 0.9×	18	1.5k

Countries citing papers authored by Neil Davie

Since Specialization

Citations

This map shows the geographic impact of Neil Davie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Davie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Davie more than expected).

Fields of papers citing papers by Neil Davie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Davie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Davie. The network helps show where Neil Davie may publish in the future.

Co-authorship network of co-authors of Neil Davie

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Davie. A scholar is included among the top collaborators of Neil Davie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Davie. Neil Davie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Galiè, Nazzareno, Friedrich Grimminger, Ekkehard Grünig, et al.. (2016). Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. The Journal of Heart and Lung Transplantation. 36(5). 509–519. 21 indexed citations

Simonneau, Gérald, Andrea Maria D’Armini, Hossein Ardeschir Ghofrani, et al.. (2014). Late-breaking abstract: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension. European Respiratory Journal. 44(Suppl 58). P1802–P1802. 7 indexed citations

Rubin, Lewis J., Nazzareno Galiè, Friedrich Grimminger, et al.. (2014). Late-breaking abstract: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension. European Respiratory Journal. 44(Suppl 58). P1803–P1803. 10 indexed citations

Mayer, Eckhard, Andrzej Biederman, Andrea Maria D’Armini, et al.. (2014). Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA). European Respiratory Journal. 44(Suppl 58). 3421–3421. 1 indexed citations

Galiè, Nazzareno, Friedrich Grimminger, Ekkehard Grünig, et al.. (2014). Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension. CHEST Journal. 145(3). 513A–513A. 3 indexed citations

Wang, Chen, Andrea Maria D’Armini, Hossein Ardeschir Ghofrani, et al.. (2014). Long-term Riociguat Treatment in Inoperable and Persistent/Recurrent CTEPH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 16-Week Phase III CHEST-1 Study and CHEST-2 Open-Label Extension. CHEST Journal. 145(3). 535B–535B. 4 indexed citations

Grünig, Ekkehard, Nazzareno Galiè, Marc Humbert, et al.. (2013). Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study. European Respiratory Journal. 42(Suppl 57). 1783–1783. 1 indexed citations

Galiè, Nazzareno, Friedrich Grimminger, Ekkehard Grünig, et al.. (2013). Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT-1 study. European Respiratory Journal. 42(Suppl 57). 1784–1784. 5 indexed citations

Mayer, Eckhard, Andrea Maria D’Armini, Hossein Ardeschir Ghofrani, et al.. (2013). Efficacy of riociguat in patients with inoperable CTEPH vs persistent/recurrent PH after pulmonary endarterectomy (PEA): Results from the phase III CHEST-1 study. European Respiratory Journal. 42(Suppl 57). 1781–1781. 2 indexed citations

10.

D’Armini, Andrea Maria, Hossein Ardeschir Ghofrani, Nick H. Kim, et al.. (2013). Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study. European Respiratory Journal. 42(Suppl 57). P2598–P2598. 1 indexed citations

11.

Ghofrani, Hossein Ardeschir, Friedrich Grimminger, Marius M. Hoeper, et al.. (2013). Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Journal. 42(Suppl 57). P3418–P3418. 3 indexed citations

12.

Ghofrani, Hossein Ardeschir, Nazzareno Galiè, Friedrich Grimminger, et al.. (2013). Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH). European Respiratory Journal. 42(Suppl 57). P3419–P3419. 1 indexed citations

13.

D’Armini, Andrea Maria, Hossein Ardeschir Ghofrani, Friedrich Grimminger, et al.. (2013). Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): 1-Year Results from the CHEST-2 Long-term Extension Study. CHEST Journal. 144(4). 1023A–1023A. 9 indexed citations

14.

Ling, Lowell, Rhoda E. Kuc, Janet J. Maguire, et al.. (2012). Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice. Life Sciences. 91(13-14). 716–722. 20 indexed citations

15.

Kosanovic, Djuro, Baktybek Kojonazarov, Himal Luitel, et al.. (2011). Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension. Respiratory Research. 12(1). 87–87. 17 indexed citations

16.

Hall, S M, Neil Davie, Nigel Klein, & Sheila G. Haworth. (2011). Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment. European Respiratory Journal. 38(4). 851–860. 19 indexed citations

17.

Gerasimovskaya, Evgenia, et al.. (2005). Extracellular Adenosine Triphosphate. CHEST Journal. 128(6). 608S–610S. 8 indexed citations

18.

Davie, Neil, Paul D. Upton, Julia M. Polak, et al.. (2002). ETA and ETB Receptors Modulate the Proliferation of Human Pulmonary Artery Smooth Muscle Cells. American Journal of Respiratory and Critical Care Medicine. 165(3). 398–405. 248 indexed citations

19.

Upton, Paul D., John Wharton, Neil Davie, et al.. (2001). Differential Adrenomedullin Release and Endothelin Receptor Expression in Distinct Subpopulations of Human Airway Smooth-Muscle Cells. American Journal of Respiratory Cell and Molecular Biology. 25(3). 316–325. 3 indexed citations

20.

Borland, Julie, et al.. (2000). Expression and function of angiotensin converting enzyme, chymase, and angiotensin II in the human radial artery and internal thoracic artery. The Annals of Thoracic Surgery. 70(6). 2054–2063. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact